
CLYM
Healthcare · Biotechnology · $608.5M market cap
$10.36-0.51 (-4.7%)Nov 13, 4:00 PM EST
Latest report
Before the open
The next earnings date isn’t on the calendar yet.
Analyst consensus
Fiscal period ending Dec 31, 2026
EPS trend, 90 days to now · +9.0% over 90 days · 30-day revisions 2 up, 1 down
Beat estimates in 3 of the last 4 reported quarters.
EPS surprise versus the estimate at the time of the report.
| Date | Session | Estimate | Actual | Surprise |
|---|---|---|---|---|
| Nov 5, 2026 | Before the open | -0.20 | -0.18 | +10.0% |
| Aug 6, 2026 | Before the open | -0.22 | -0.18 | +18.2% |
| May 7, 2026 | Before the open | -0.30 | -0.20 | +33.3% |
| Mar 9, 2026 | Time not confirmed | -0.19 | -0.26 | -38.9% |
| Nov 6, 2025 | Before the open | -0.15 | -0.19 | -26.7% |
| Aug 14, 2025 | Before the open | -0.18 | -0.13 | +27.8% |
| May 14, 2025 | Time not confirmed | -0.15 | -0.31 | -106.7% |
| Mar 25, 2025 | After the close | -0.15 | 0.04 | +126.7% |
| Nov 12, 2024 | Time not confirmed | — | -0.13 | — |
| Aug 14, 2024 | Time not confirmed | — | -1.81 | — |
| May 13, 2024 | Time not confirmed | — | -0.06 | — |
| Mar 4, 2024 | Time not confirmed | -0.13 | -0.13 | -1.1% |
| Nov 6, 2023 | Time not confirmed | -0.14 | -0.15 |
Climb Bio, Inc., a clinical-stage biotechnology company, focuses on developing therapies to address unmet needs for patients living with immune-mediated diseases. The company's lead product candidate is the budoprutug, an anti-CD19 monoclonal antibody for the treatment of B-cell mediated diseases. It is also developing budoprutug which is in phase 2 clinical trials for the treatment of primary membranous…
| -4.7% |
| Sep 11, 2023 | Time not confirmed | -0.16 | -0.19 | -21.6% |
| May 11, 2023 | After the close | -0.25 | -0.84 | -236.0% |
| Mar 6, 2023 | Time not confirmed | -0.33 | -0.29 | +12.1% |
| Nov 14, 2022 | Before the open | -0.43 | -0.37 | +14.0% |
| Aug 15, 2022 | Before the open | -0.47 | -0.56 | -19.1% |
| May 16, 2022 | Time not confirmed | -0.50 | -0.50 | 0.0% |
| Mar 7, 2022 | After the close | -0.63 | 1.25 | +298.4% |
| Nov 8, 2021 | After the close | -0.85 | -0.70 | +17.6% |
| Jul 16, 2021 | Time not confirmed | -2.37 | -0.61 | +74.3% |